Lifecare ASA - Director's Dealing 2023

LIFE: Notofication of trade by party closely related to primary insider

Bergen, Norway, December 15th, 2023. Islay Ventures GmbH ("IV") a company

wholly owned and controlled by Lifecare CSO Prof. Dr. Dr. Med Andreas

Pfützner, has today reported to have sold 320,800 shares in the Company at an

average price of NOK 3.476. The transaction represents 12,24% of IV's original

holding.

After the transaction IV owns 2.299.699 shares in Lifecare, and IV has

accepted a lock-up period of 12 months for the remaining holdling. In addition

to the indirect holding through IV, Prof. Pfützner is allocated 1.048.058

share options in Lifecare.

The transaction is related to financial needs due to a restructuring of IV and

its subsidiaries, including transforming Prof. Pfützner's relationship to

Lifecare from a consultancy agreement to traditional employment with effect

from January 1st, 2024.

About us

Lifecare AS is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, [email protected], +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs,

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR Article 19 no. 3. The information was submitted for publication

at 2023-12-15 17:45 CET.

AI assistant